ライフサイエンスコーパス: maculopapular

1 of 127 patients), rash (13 [10%]), and rash maculopapular (11 [9%]).

2 ] of 127 patients), rash (12 [9%]), and rash maculopapular (12 [9%]).

3 significant grade 3-4 toxicity was rash (14% maculopapular, 8.6% acneiform).

4 kin involvement was heterogeneous, including maculopapular (82%), nodular (6%), and diffuse cutaneous

5 He also developed a maculopapular and erythematous rash in the groin, genita

6 ical features of PAAND-recurrent episodes of maculopapular and pustular rash, gastrointestinal involv

7 ly modified, with fewer skin lesions, mostly maculopapular, and milder presentation.

8 11.5 and >=20.0 ng/mL, REMA >=2, monomorphic maculopapular CM (MPCM), and elevated BST based upon try

9 In particular, we recommend that the typical maculopapular cutaneous lesions (urticaria pigmentosa) s

10 Based on these findings, maculopapular cutaneous mastocytosis (MPCM) was diagnose

11 e hundred twenty-two patients presented with maculopapular cutaneous mastocytosis (MPCM), 12 patients

12 lished findings from a pediatric cohort with maculopapular cutaneous mastocytosis (MPCM).

13 e (sbT) levels in 111 children with MIS - 80 maculopapular cutaneous mastocytosis/plaque mastocytosis

14 t of drug hypersensitivity reactions such as maculopapular drug rashes (MDR).

15 ogic immune-related adverse events including maculopapular eruption, lichenoid reactions, pruritus, a

16 Vesicular, urticarial, and maculopapular eruptions and livedo, necrosis, and other

17 this syndrome is a severe diffuse cutaneous maculopapular exanthem that is similar to the exanthem a

18 ulanic acid (AX-CLV) (31%); and the symptoms maculopapular exanthema (MPE) (34%) and unknown reaction

19 nic acid (CLV) (26.8%) and the main symptoms maculopapular exanthema (MPE) (49.5%) and delayed-urtica

20 estricted to patients reporting nonimmediate maculopapular exanthema or urticaria/angioedema.

21 Drug-induced maculopapular exanthemas (MPEs) are mediated by Th1 CD4(

22 aneous adverse reactions (35/102, 34.3%) and maculopapular exanthems (33/102, 32.4%).

23 ccinated persons (fewer skin lesions, mostly maculopapular) has made it more challenging for provider

24 the development of one or more erythematous maculopapular lesions that evolve over the course of sev

25 nts, namely a monomorphic variant with small maculopapular lesions, which is typically seen in adult

26 action in skin biopsies from 3 patients with maculopapular or nodular post-kala-azar dermal leishmani

27 varicella in the differential diagnosis of a maculopapular or vesicular rash.

28 appearing most frequently as a desquamating, maculopapular, papulopustular, and/or erythematous diffu

29 Maculopapular pruritic exanthema occurred in 20% of pati

30 The subtypes of cirAEs included maculopapular, pruritus, lichenoid, immunobullous, psori

31 e most common were increased lipase (17.8%), maculopapular rash (11.1%), and fatigue (11.1%).

32 d y-glutamyltransferase (20 [15%] patients), maculopapular rash (16 [12%]), and anaemia (15 [11%]); 7

33 ransferase, 17% aspartate aminotransferase), maculopapular rash (17%), and neutropenia (17%).

34 n patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutrope

35 e events of all grades were mucositis (70%), maculopapular rash (51%), and nausea (43%).

36 hatemia (14.0%), neutrophil decrease (9.3%), maculopapular rash (7.0%), and anemia (7.0%).

37 with chemotherapy versus enfortumab vedotin; maculopapular rash (7.4% versus 0%), fatigue (6.8% versu

38 79-related adverse events of all grades were maculopapular rash (76%), mucositis (70%), asthenia (50%

39 ated creatine phosphokinase (five [10%]) and maculopapular rash (five [10%]).

40 gue (in 51%), hypophosphatemia (in 42%), and maculopapular rash (in 32%); 95% of adverse events were

41 ies, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased lipase (n = 1), an

42 ents were neutropenia (eight [9%] patients), maculopapular rash (seven [8%] patients), and fatigue (s

43 of an inclusive case definition (generalized maculopapular rash and fever), and the specificity is in

44 400 mg dose who developed a severe (grade 3) maculopapular rash and terminated treatment.

45 c toxicity consisted of grade 3 erythematous maculopapular rash observed in one patient at 12 mg/m(2)

46 s after transplant with fever, diarrhea, and maculopapular rash on her palms, soles, and back.

47 Extensive maculopapular rash on the skin was consistent with graft

48 se of varicella was defined as a generalized maculopapular rash that developed in a facility resident

49 in the durvalumab-tremelimumab alone group (maculopapular rash), five (19%) patients in the low-dose

50 ade 3 stomatitis/oral mucositis, and grade 3 maculopapular rash).

51 s case was defined as an illness with fever, maculopapular rash, and either cough, coryza or conjunct

52 terised by fever, a generalised erythematous maculopapular rash, and lymphadenopathy.

53 ompanied by clinical symptoms such as fever, maculopapular rash, and/or lymphadenopathy.

54 es included a pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection,

55 elevated amylase (three [4%]), and fatigue, maculopapular rash, dyspnoea, decreased lymphocyte count

56 ion was examined that included a generalized maculopapular rash, fever (>or=38.3 degrees C, if measur

57 ith nine patients under observation (grade 4 maculopapular rash, grade 3 nausea, grade 3 infection, g

58 d patients characteristically present with a maculopapular rash, often accompanied by an inoculation

59 and grade 3 pulmonary infection with grade 3 maculopapular rash.

60 er, immune suppression, and a characteristic maculopapular rash.

61 ifesting as nonspecific fever, headache, and maculopapular rash.

62 tent children is associated with a fever and maculopapular rash.

63 limited clinical symptoms, including diffuse maculopapular rash.

64 ions of eczema and one developed a transient maculopapular rash.

65 eruptions are classically diffuse, symmetric maculopapular rashes involving trunk and extremities.

66 es a mild, relatively localized erythematous maculopapular skin rash in most dengue-naive vaccinees.

67 Two patients developed erythematous, maculopapular to papular eruptions confined to the VCA,

68 e with lymphadenopathy followed by a diffuse maculopapular to vesiculopustular skin/mucosal lesion er

69 ) in 13 (25%) of 51 low-dose vaccinees, with maculopapular, vesicular dermatitis, or both in seven (5